IDH1 and central nervous system cancer: A significant proportion of low grade gliomas (>85%) and a smaller proportion of glioblastomas contain mutations in IDH1 or IDH2, which have been shown to associate with a specific hypermethylated phenotype and predict better overall survival for those patients [79,80,81,82,83].